Literature DB >> 33691940

Targeted therapies for resectable lung adenocarcinoma: ADAURA opens for thoracic oncologic surgeons.

David R Jones1, Yi-Long Wu2, Masahiro Tsuboi3, Roy S Herbst4.   

Abstract

Entities:  

Keywords:  ADAURA; EGFR; lung adenocarcinoma; osimertinib

Mesh：

Substances：

Year:  2021        PMID： 33691940      PMCID： PMC8519337          DOI： 10.1016/j.jtcvs.2021.02.008

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN： 0022-5223            Impact factor:   6.439


× No keyword cloud information.
  14 in total

1.  The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer.

Authors:  Matthew P Smeltzer; Murry W Wynes; Sylvie Lantuejoul; Ross Soo; Suresh S Ramalingam; Marileila Varella-Garcia; Meghan Meadows Taylor; Kristin Richeimer; Kelsey Wood; Kristen E Howell; Mercedes Lilana Dalurzo; Enriqueta Felip; Gina Hollenbeck; Keith Kerr; Edward S Kim; Clarissa Mathias; Jose Pacheco; Pieter Postmus; Charles Powell; Masahiro Tsuboi; Ignacio I Wistuba; Heather A Wakelee; Chandra P Belani; Giorgio V Scagliotti; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2020-05-20       Impact factor: 15.609

2.  Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.

Authors:  Dongsheng Yue; Shidong Xu; Qun Wang; Xiaofei Li; Yi Shen; Heng Zhao; Chun Chen; Weimin Mao; Wei Liu; Junfeng Liu; Lanjun Zhang; Haitao Ma; Qiang Li; Yue Yang; Yongyu Liu; Haiquan Chen; Changli Wang
Journal:  Lancet Respir Med       Date:  2018-08-24       Impact factor: 30.700

3.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

4.  Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma.

Authors:  Whitney S Brandt; Ilies Bouabdallah; Kay See Tan; Bernard J Park; Prasad S Adusumilli; Daniela Molena; Manjit S Bains; James Huang; James M Isbell; Matthew J Bott; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2017-11-13       Impact factor: 5.209

5.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

6.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Authors:  C Zhou; Y L Wu; G Chen; J Feng; X-Q Liu; C Wang; S Zhang; J Wang; S Zhou; S Ren; S Lu; L Zhang; C Hu; C Hu; Y Luo; L Chen; M Ye; J Huang; X Zhi; Y Zhang; Q Xiu; J Ma; L Zhang; C You
Journal:  Ann Oncol       Date:  2015-07-03       Impact factor: 32.976

7.  Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Authors:  Bishal Gyawali; Howard Jack West
Journal:  J Clin Oncol       Date:  2020-12-04       Impact factor: 44.544

8.  Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yu-Cheng Wei; Yong-Yu Liu; Chun Chen; Ying Cheng; Rong Yin; Fan Yang; Sheng-Xiang Ren; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Jin-Ji Yang; Hong-Hong Yan; Xue-Ning Yang; Si-Yang Liu; Qing Zhou; Yi-Long Wu
Journal:  J Clin Oncol       Date:  2020-12-17       Impact factor: 44.544

9.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Authors:  Suresh S Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng-Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2019-11-21       Impact factor: 91.245

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more
  3 in total

1.  Intraoperative Lymph Node Management During Non-small Cell Lung Cancer Surgery.

Authors:  Michael R Gooseman; Alessandro Brunelli
Journal:  Ann Surg Oncol       Date:  2021-04-16       Impact factor: 5.344

Review 2.  Targeted Therapy in Early Stage Non-small Cell Lung Cancer.

Authors:  Si-Yang Liu; Si-Yang Maggie Liu; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Curr Treat Options Oncol       Date:  2022-07-25

3.  Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).

Authors:  Marius Ilié; Véronique Hofman; Christophe Bontoux; Simon Heeke; Virginie Lespinet-Fabre; Olivier Bordone; Sandra Lassalle; Salomé Lalvée; Virginie Tanga; Maryline Allegra; Myriam Salah; Doriane Bohly; Jonathan Benzaquen; Charles-Hugo Marquette; Elodie Long-Mira; Paul Hofman
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.